AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
CompanyDrug

AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts
Company

AstraZeneca Pauses GBP 200m Cambridge R&D Investment Amid UK Funding Cuts

Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial
CompanyDrug

Novo Nordisk Rybelsus Gains Cardio Benefit from SOUL Trial

Guangzhou Baiyunshan Pharmaceutical Launches Phase I/II Trial for RET‑Targeted BYS10
Drug

Guangzhou Baiyunshan Pharmaceutical Launches Phase I/II Trial for RET‑Targeted BYS10

Sino Biopharmaceutical Secures NMPA Approval for Degarelix Generic in China
CompanyDrug

Sino Biopharmaceutical Secures NMPA Approval for Degarelix Generic in China

Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis‑Related Pruritus
CompanyDrug

Haisco Pharma Secures NMPA Approval for Anrikefon in Hemodialysis‑Related Pruritus

Monte Rosa Therapeutics and Novartis Partner on Degrader Development
CompanyDeals

Monte Rosa Therapeutics and Novartis Partner on Degrader Development

Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy
Drug

Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy

Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
CompanyDrug

Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine

BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials
Drug

BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials

Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
CompanyDeals

Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Drug

Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application